Brand Name(s): Zenapax
CAS nš: 152923-56-3
(dah KLIH zyoo mab)
What is Daclizumab?
Daclizumab is an immunosuppressant. It decreases the actions of the body's immune system.
This medicine is used to prevent the body from rejecting a transplanted kidney. Daclizumab is usually used as part of a treatment regimen including other medications.
In the United Kingdom, the National Institute for Health and Clinical Excellence has recommended its use be considered for all kidney transplant recipients.
Latest News
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Background: Immunosuppressive regimens with the fewest possible toxic effects are desirable for...
[more]Roche Gives Up Daclizumab; PDL Seeking Asthma Partner
Hoffmann-La Roche Inc.'s decision to back out entirely of the deal with PDL BioPharma Inc. for...
[more]Micromet Presents New Anti-IL-2 Antibody with Unique Mode of Action
Potential against Inflammatory Diseases, T Cell Leukemia and Transplant Rejection
[more]Zenapax (daclizumab): Hopes raised for effectiveness of multiple sclerosis drug
A national research team led by the University of Cincinnati's Bibiana Bielekova, MD, report new...
[more]Research: Daclizumab Method of Action Surprises Researchers
Biogen's Daclizumab has recently surprised researchers with its method of action. Daclizumab, known...
[more]